<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04527484</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-1314-105</org_study_id>
    <nct_id>NCT04527484</nct_id>
  </id_info>
  <brief_title>A Bioequivalence Study to Compare Two Formulations of SHR-1314 After Subcutaneous Injection in Healthy Subjects</brief_title>
  <official_title>A Single-center, Randomized, Parallel, Open-label , Bioequivalence Study to Compare the Two Formulations of SHR-1314 After Subcutaneous Injection in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be a single-center, randomized, parallel, open-label, single dosing bridging&#xD;
      study in healthy subjects to evaluate bioequivalence of two formulations of SHR-1314.&#xD;
      Subjects will be randomly assigned to the Vials group, the PFS group at a ratio of 1:1&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 20, 2020</start_date>
  <completion_date type="Anticipated">March 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 10, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-last: Area under the serum concentration-time curve from time zero to the last measurable concentration</measure>
    <time_frame>from Day1 to Day113</time_frame>
    <description>Compare the AUC0-last of 240mg subcutaneous injection of two specifications of SHR-1314 injection in healthy subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax: Observed maximum serum concentration</measure>
    <time_frame>from Day1 to Day113</time_frame>
    <description>Compare the Cmax of 240mg subcutaneous injection of two specifications of SHR-1314 injection in healthy subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞: Area under the serum concentration-time curve from time zero to infinity</measure>
    <time_frame>from Day1 to Day113</time_frame>
    <description>Compare the AUC0-∞ of 240mg subcutaneous injection of two specifications of SHR-1314 injection in healthy subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax : Time at which observed maximum concentration occurs</measure>
    <time_frame>from Day1 to Day113</time_frame>
    <description>Compare the Tmax of 240mg subcutaneous injection of two specifications of SHR-1314 injection in healthy subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F: Apparent clearance</measure>
    <time_frame>from Day1 to Day113</time_frame>
    <description>Compare the CL/F of 240mg subcutaneous injection of two specifications of SHR-1314 injection in healthy subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2: Terminal half-life</measure>
    <time_frame>from Day1 to Day113</time_frame>
    <description>Compare the t1/2 of 240mg subcutaneous injection of two specifications of SHR-1314 injection in healthy subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>V/F:Apparent volume of distribution</measure>
    <time_frame>from Day1 to Day113</time_frame>
    <description>Compare the V/F of 240mg subcutaneous injection of two specifications of SHR-1314 injection in healthy subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events (AEs).</measure>
    <time_frame>from Day1 to Day113</time_frame>
    <description>Compare Incidence and severity of AE at 240mg subcutaneous injection of two specifications of SHR-1314 injection in healthy subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug Antibodies (ADAs)</measure>
    <time_frame>from Day1 to Day113</time_frame>
    <description>Incidence of development of Anti-drug Antibodies (ADAs) during the course of the study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Bioequivalence</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SHR-1314 Vial</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SHR-1314 PFS</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1314</intervention_name>
    <description>each group subjects will be given different formulations of SHR-1314</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent must be obtained before any assessment is performed.Subjects&#xD;
             must be able to understand and communicate with the investigator and comply with the&#xD;
             requirements of the study and must give a written, signed and dated informed consent&#xD;
             before any study related activity is performed. Where relevant, a legal representative&#xD;
             will also sign the informed study consent according to local laws and regulations&#xD;
&#xD;
          -  Men or women at least 18 years and no more than 45 years of age at time of screening.&#xD;
&#xD;
          -  Men with a body weight ≥50 kg or women with a body weight ≥45kg, with BMI range from&#xD;
             18 to 25.&#xD;
&#xD;
          -  Subjects with normal physical examination results and with normal laboratory results&#xD;
             (blood, chemistry, urine, drug screening, coagulation function test), ECG and X-ray&#xD;
             chest test are normal or with certain abnormal without clinical significance.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of significant medical problems, with investigator's judge that not proper to&#xD;
             participate clinical study&#xD;
&#xD;
          -  History of hypersensitivity to any of study drug constituent&#xD;
&#xD;
          -  History or current infection with human immunodeficiency virus (HIV) or hepatitis C;&#xD;
             or current hepatitis B infection or syphilis&#xD;
&#xD;
          -  History of lymphoproliferative disease or any known malignancy or history of&#xD;
             malignancy of any organ system within the past 5 years&#xD;
&#xD;
          -  History of chronic or recurrent infectious disease, or evidence of active or latent&#xD;
             tuberculosis infection.&#xD;
&#xD;
          -  Those who have participated in any clinical study for any drug or medical device&#xD;
             within 3 months before screening&#xD;
&#xD;
          -  Those who have been vaccinated with live attenuated vaccine within 12 weeks prior to&#xD;
             screening&#xD;
&#xD;
          -  History or evidence of ongoing alcohol or drug abuse, within the last six months&#xD;
             before Baseline.&#xD;
&#xD;
          -  Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a&#xD;
             female after conception and until the termination of gestation, confirmed by a&#xD;
             positive hCG laboratory test.&#xD;
&#xD;
          -  Subjects judged by the investigator as unsuitable for participating in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Qian Xu, Ph.D</last_name>
    <phone>0186 021-68868370</phone>
    <email>PRS_admin@hrglobe.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jianjun Zou, Ph.D</last_name>
    <phone>0186 021-68868370</phone>
    <email>PRS_admin@hrglobe.cn</email>
  </overall_contact_backup>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 23, 2020</study_first_submitted>
  <study_first_submitted_qc>August 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2020</study_first_posted>
  <last_update_submitted>August 23, 2020</last_update_submitted>
  <last_update_submitted_qc>August 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

